2001
DOI: 10.1006/abio.2001.5298
|View full text |Cite
|
Sign up to set email alerts
|

Allophycocyanin 1 as a Near-Infrared Fluorescent Tracer: Isolation, Characterization, Chemical Modification, and Use in a Homogeneous Fluorescence Resonance Energy Transfer System

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
35
0

Year Published

2004
2004
2017
2017

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 38 publications
(35 citation statements)
references
References 27 publications
0
35
0
Order By: Relevance
“…7D). It is known that APC organization may change depending on the ionic environment and/or the APC concentration itself (45). When concentrated enough (A max Ͼ 0.1), APC was mostly in the trimeric form (␣␤) 3 and its absorption and fluorescence emission maxima were 651 and 661 nm, respectively (Fig.…”
Section: Resultsmentioning
confidence: 99%
“…7D). It is known that APC organization may change depending on the ionic environment and/or the APC concentration itself (45). When concentrated enough (A max Ͼ 0.1), APC was mostly in the trimeric form (␣␤) 3 and its absorption and fluorescence emission maxima were 651 and 661 nm, respectively (Fig.…”
Section: Resultsmentioning
confidence: 99%
“…Homogeneous Time-resolved Fluorescence (HTRF)-Monoclonal anti-CX3CR1 (clone 51637) was labeled with the different fluorescent donors or acceptors as described previously (24,25). The donor was a pyridine-bipyridine (PBP) europium cryptate (europium cryptate-PBP).…”
Section: Methodsmentioning
confidence: 99%
“…It consists of two different subunits, a and ß, with apparent molecular masses of 19.5 and 17.4 kDa (Sun & Wang 2003). APC has uses not only as the particularly bright fluorescent protein commonly used in flow cytometry (Kronick 1986), but also as an acceptor in a fluorescence resonance energy transfer system (Trinquet et al 2001). In addition, our previous reports have revealed that rAPC could remarkably inhibit the S-180 carcinoma in mice (Tang et al 1996Zhao et al 2003;Ge et al 2005), which indicated that rAPC might be used as a potential pharmaceutical product.…”
Section: Introductionmentioning
confidence: 98%